Media Updates

PARIS, FRANCE, 23 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that Beech Tree, which holds directly and indirectly 26.03% of the share capital and 33.05% of the voting rights of Ipsen SA, announces that Altawin, Fondation Alasol…

PARIS, FRANCE 30 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today a new global collaboration and option agreement with Origami Therapeutics for a research stage protein degrader program targeting genetic neurodegenerative diseases. Following a successful drug candidate nomination,…

PARIS, FRANCE, 9 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) is aware of recent updates on the potential challenges with regards to the manufacturing and availability of generic lanreotide in several markets. Ipsen stands ready to supply Somatuline (60mg, 90mg, 120mg) at the volumes required to address patient needs in all markets where we are present.

PARIS, FRANCE AND MONTREAL, CANADA 22 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR, of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, announced today a new research collaboration…

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative…